December, 2019: BioAegis Therapeutics Announces Publication: “Delayed Administration of Recombinant Plasma Gelsolin Improves Survival in a Murine Model of Severe Influenza”
MORRISTOWN, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) — BioAegis Therapeutics, Inc., a clinical stage company developing technology to address injurious inflammation while protecting immune function and vital organs in diseases driven by inflammation and infection, announces publication of new research findings with recombinant human plasma gelsolin in influenza. The research demonstrates that recombinant human plasma …